MARAVAI LIFESCIENCES ($NASDAQ:MRVI) reported total revenue of USD 68.9 million for the second quarter of fiscal year 2023, which was a 71.6% decrease from the same quarter of the previous year. Instead of the net income of USD 71.2 million recorded in the prior year, the company experienced a net loss of USD 6.5 million. This was reported on June 30, 2023.
The company’s stock opened at $11.4 and closed at $11.0, down 4.2% from the prior closing price of $11.5. This reflects the market’s reaction to MARAVAI LIFESCIENCES‘ financial results for the quarter. Despite the drop in the stock price, MARAVAI LIFESCIENCES has reported strong growth in its revenue, operating profit, and net income.
The company’s strong results are indicative of their ability to leverage their core competencies and expand into new markets. Going forward, investors will be looking for MARAVAI LIFESCIENCES to continue its strong performance and deliver further growth in revenue and profitability. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Maravai Lifesciences. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Maravai Lifesciences. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Maravai Lifesciences. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Maravai Lifesciences are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Maravai Lifesciences Stock Fair Value
At GoodWhale, we have conducted a financial analysis of MARAVAI LIFESCIENCES and have concluded that the fair value of its share is around $21.9. This was calculated by our proprietary Valuation Line. Unfortunately, the current price of the share is only $11.0, meaning that MARAVAI LIFESCIENCES is currently undervalued by 49.8%. We encourage any investors looking at MARAVAI LIFESCIENCES to take this into consideration when making their decisions. More…
Risk Rating Analysis
Star Chart Analysis
The competition between Maravai LifeSciences Holdings Inc and its competitors is fierce. Takara Bio Inc, Forward Pharma A/S, Obio Technology (shanghai) Corp Ltd are all trying to gain market share in the rapidly growing life sciences market. Maravai LifeSciences Holdings Inc has a strong product portfolio and is well-positioned to compete in this market.
– Takara Bio Inc ($TSE:4974)
Takara Bio Inc. is a Japanese biotechnology company that specializes in the development, manufacturing, and marketing of biotechnology products. The company was founded in 1953 and is headquartered in Kyoto, Japan. Takara Bio has four main business segments: biopharmaceuticals, bio-agriculture, bio-industry, and diagnostics. The company’s products include enzymes, proteins, antibodies, and nucleic acids used in research and development, drug discovery, and diagnostic applications. Takara Bio also offers agricultural products, such as plant growth regulators and soil amendments. In addition, the company provides contract research and development services.
– Forward Pharma A/S ($NASDAQ:FWP)
Write a paragraph on it’s market cap and ROE and a brief intro of what the company does:
Forward Pharma A/S has a market cap of 22.41M as of 2022, a Return on Equity of -3.32%. The Company is focused on developing and commercializing therapies for the treatment of inflammatory diseases.
– Obio Technology (shanghai) Corp Ltd ($SHSE:688238)
Obio Technology (shanghai) Corp Ltd is a publicly traded company with a market cap of 11.59B as of 2022. The company has a return on equity of 2.0%. The company is engaged in the business of providing technology solutions to businesses and consumers. The company’s products and services include software, hardware, and services. The company’s customers include businesses of all sizes, government entities, and individual consumers.
MARAVAI LIFESCIENCES reported a significant decline in earnings for the second quarter of the 2023 fiscal year. Revenue dropped by 71.6%, leading to a net loss of USD 6.5 million, compared to 71.2 million in net income reported for the same quarter last year. This resulted in a decrease in the stock price of MARAVAI LIFESCIENCES on the same day.
Investors should consider this news as a sign of a negative outlook for the company and may want to adjust their portfolios accordingly. Long-term investors may also take this opportunity to enter at discounted prices if they believe MARAVAI LIFESCIENCES has potential for recovery in the future.